Pentair Announces Quarterly Cash Dividend of $0.23
Pentair Announces Quarterly Cash Dividend of $0.23
Pentair plc (NYSE: PNR) announced today that it will pay a regular quarterly cash dividend of $0.23 per share on November 1, 2024 to shareholders of record at the close of business on October 18, 2024. This is the 48th consecutive year that Pentair has increased its dividend.
ABOUT PENTAIR PLC
At Pentair, we help the world sustainably move, improve, and enjoy water, life’s most essential resource. From our residential and commercial water solutions, to industrial water management and everything in between, Pentair is a core large cap value equity stock focused on smart, sustainable water solutions that help our planet and people thrive.
Pentair had revenue in 2023 of approximately $4.1 billion, and trades under the ticker symbol PNR. With approximately 10,500 global employees serving customers in more than 150 countries, we work to help improve lives and the environment around the world. To learn more, visit www.pentair.com.
Pentair Contacts:
Shelly Hubbard
Vice President, Investor Relations
Tel: 763-656-5575
E-mail: shelly.hubbard@pentair.com
Rebecca Osborn
Senior Director, Communications
Tel: 763-656-5589
Email: rebecca.osborn@pentair.com
View source version on businesswire.com: https://www.businesswire.com/news/home/20240923391971/en/
-
6 Top-Performing Large-Growth Funds
-
What’s the Difference Between the CPI and PCE Indexes?
-
Micron Earnings: Great Guidance but Stock Now Looks Fairly Valued
-
August PCE Report Forecasts Show More Good News on Inflation
-
AI Stocks May Be Down, but Don’t Count Them Out
-
4 Stocks to Buy as the Fed Cuts Interest Rates
-
Markets Brief: The Uncertain Path to Neutral Interest Rates
-
What’s Happening in the Markets This Week
-
Our Top Pick for Investing in US Renewable Energy
-
How to Measure a Stock’s Uncertainty
-
How to Determine Whether a Stock Is Cheap, Expensive, or Fairly Valued
-
Why a Company’s Management and Capital Allocation Matter
-
How to Determine What a Stock Is Worth
-
How to Measure a Company’s Competitive Advantage
-
How to Think Like a Stock Analyst
-
How GLP-1 Drugs Like Ozempic Are Boosting Biopharma Stocks